Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder CancerPRNewsWire • 01/31/24
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas PharmaBusiness Wire • 01/04/24
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage EngagerPRNewsWire • 12/28/23
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged ChildrenPRNewsWire • 12/17/23
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay TherapeuticsPRNewsWire • 12/13/23
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with MenopausePRNewsWire • 12/10/23
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell TherapiesBusiness Wire • 11/30/23
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone TherapyPRNewsWire • 11/29/23
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet NeurologyPRNewsWire • 11/15/23
Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, JapanPRNewsWire • 10/11/23